Macrogenics Analyst Ratings
H.C. Wainwright Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4
Evercore ISI Sticks to Their Buy Rating for MacroGenics (MGNX)
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $6
Evercore Maintains Macrogenics(MGNX.US) With Buy Rating
MacroGenics (MGNX) Receives a Hold From TD Cowen
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target
Macrogenics Analyst Ratings
H.C. Wainwright Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Medtronic (MDT)
Citi Maintains Macrogenics(MGNX.US) With Buy Rating, Cuts Target Price to $14
Macrogenics Analyst Ratings
Buy Rating Affirmed for MacroGenics: Potential Growth Amid Oncology Trials and Solid Financials
MacroGenics (MGNX) Receives a Buy From Barclays
Buy Rating Affirmed for MacroGenics Ahead of ESMO Meeting Amidst Positive Financials and Speculative Growth Scenarios
Macrogenics Price Target Cut to $5.00/Share From $8.00 by BMO Capital
Macrogenics Analyst Ratings
Maintaining Hold on MacroGenics: Discontinued Vobra Duo and Low Conviction in Competitive Market
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating